OCGN (Ocugen) Cash And Cash Equivalents : $58.51 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ocugen Cash And Cash Equivalents?

Ocugen's quarterly cash and cash equivalents increased from Jun. 2024 ($15.70 Mil) to Sep. 2024 ($38.70 Mil) and increased from Sep. 2024 ($38.70 Mil) to Dec. 2024 ($58.51 Mil).

Ocugen's annual cash and cash equivalents declined from Dec. 2022 ($77.56 Mil) to Dec. 2023 ($39.46 Mil) but then increased from Dec. 2023 ($39.46 Mil) to Dec. 2024 ($58.51 Mil).

Ocugen Cash And Cash Equivalents Historical Data

The historical data trend for Ocugen's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Cash And Cash Equivalents Chart

Ocugen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

24.04

94.96

77.56

39.46

58.51

Ocugen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															39.46	26.38	15.70	38.70	58.51

Ocugen Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Ocugen (NAS:OCGN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Ocugen Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Ocugen's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

OCGN:Mexico 2H51:Germany 2H51:Germany 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Executives

Prabhavathi Fernandes	director	114 MILTON AVENUE, CHAPEL HILL NC 27514
Kirsten Castillo	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Junge Zhang	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu	officer: CFO/CBO	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri	director, officer: Chief Executive Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay	officer: Chief Scientific Officer	C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar	director	375 PHEASANT RUN, NEWTOWN PA 18940
Uday Kompella	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Marna C Whittington	director	2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo	officer: CAO/SVP, Finance	C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian	officer: Chief Financial Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti	director	C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355